Related Experiment Videos
Adjuvant and neoadjuvant treatments for NSCLC
Everett E Vokes1, Hak Choy, David Gandara
1Section of Hematology/Oncology and Cancer Research Center, University of Chicago, 5841 S Maryland Ave MC 2115, Chicago, IL 60637-1470, USA. evokes@medicine.bsd.uchicago.edu
Lung Cancer (Amsterdam, Netherlands)
|December 14, 2002
Summary
Concurrent chemoradiotherapy significantly improves survival for stage III non-small cell lung cancer (NSCLC) patients. Adding docetaxel consolidation further enhances outcomes, showing promising survival data in phase II studies.
Area of Science:
- Oncology
- Medical Research
Background:
- Stage III non-small cell lung cancer (NSCLC) treatment has evolved significantly.
- Induction chemotherapy offers a survival benefit, but concurrent chemoradiotherapy has emerged as a superior strategy.
Purpose of the Study:
- To evaluate the efficacy of concurrent chemoradiotherapy, particularly with docetaxel, in stage III NSCLC.
- To assess the impact of docetaxel consolidation following chemoradiotherapy.
Main Methods:
- Review of treatment strategies including induction chemotherapy, hyperfractionated radiotherapy, and concurrent chemoradiotherapy.
- Analysis of phase II study SWOG 9504 involving cisplatin/etoposide concurrent chemoradiotherapy followed by docetaxel consolidation.
- Evaluation of neoadjuvant docetaxel in stage III NSCLC patients eligible for radical treatment.
Main Results:
- Concurrent chemoradiotherapy improves locoregional control and median survival by 3-4 months compared to induction chemotherapy.
- SWOG 9504 demonstrated a median survival of 26 months, with 1-year and 3-year survival rates of 76% and 40%, respectively.
- Neoadjuvant docetaxel in radical treatment-eligible patients is tolerable and shows a trend towards increased survival.
Conclusions:
- Concurrent chemoradiotherapy is the most successful strategy for stage III NSCLC, offering improved survival.
- Docetaxel consolidation after concurrent chemoradiotherapy yields highly encouraging survival data, warranting further investigation.
- Neoadjuvant docetaxel may be a beneficial addition for select stage III NSCLC patients.